血脂康（胶囊）临床应用中国专家共识（2017修订版）

Chinese expert consensus on the use of Xuezhikang （2017 revised edition）

一、背景 血脂异常是导致动脉粥样硬化性心血管疾病（atherosclerotic cardiovascular disease，ASCVD）的重要原因。近年来，我国血脂异常的患病率大幅度增加，ASCVD防治面临严峻挑战。大量临床研究证据表明，他汀类药物降低低密度脂蛋白胆固醇（low-density lipoprotein cholesterol，LDL-C），

Xuezhikang, a Chinese traditional medicine, contains natural statin and is effective on dyslipidemia by inhibiting cholesterol synthesis. Xuezhikang therapy for 8 weeks in patients with hyperlipidemia reduced total cholesterol （TC） by 23％, low density lipoprotein cholesterol （LDL-C） by 28.5％and triglyceride（TG） by 36.5％ , and increased high density lipoprotein cholesterol （HDL-C） by 19.6％ , respectively. Data from China Coronary Secondary Prevention Study （CCSPS） showed that treatment with Xuezhikang lowered the risks of major coronary events, death from coronary heart disease, and all cause death in patients with myocardial infarction, indicating that Xuezhikang can be used in the primary and secondary prevention of cardiovascular disease.